The post 3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge appeared first on InvestorPlace.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In the biotech and pharmaceutical world, FDA approval is the ...

U.S. futures fell Thursday, with investors concentrating on corporate earnings, particularly from the highly-valued tech ...

The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the ...

For the remainder of 2024, Merck has raised its financial projections. It now anticipates worldwide sales of $63.1 billion and $64.3 billion, reflecting the positive momentum it saw in Q1. The company ...

Merck on Thursday reported first-quarter results that beat analysts’ expectations amid strong sales of vaccines and cancer ...

For the quarter ended March 2024, Merck (MRK) reported revenue of $15.78 billion, up 8.9% over the same period last year. EPS came in at $2.07, compared to $1.40 in the year-ago quarter. The reported ...

Bristol-Myers Squibb (BMY) stock dips even as the company topped consensus with Q1 2024 results, despite headwinds in its ...

ImmunityBio finally received FDA approval for its drug ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with ...

Meeting of ASCO is a major event for clinicians and researchers in the field of oncology. Explore more details here.